Haemonetics earnings were $175.4M for the trailing 12 months ending Dec 27, 2025, with 42.6% growth year over year. The latest HAE earnings report on Dec 27, 2025 announced Q4 2025 earnings of $44.7M, up 15.7% from last quarter. For the last reported fiscal year 2025 ending Mar 29, 2025, HAE reported annual earnings of $167.7M, with 42.6% growth.
HAE past earnings growth
How has HAE's earnings growth performed historically?
On HAE's earnings call on Invalid Date, Haemonetics (NYSE: HAE) reported Q4 2025 earnings per share (EPS) of $0.96, up 28% year over year. Total HAE earnings for the quarter were $44.74 million. In the same quarter last year, Haemonetics's earnings per share (EPS) was $0.75.
As of the last Haemonetics earnings report, Haemonetics is currently profitable. Haemonetics's net profit (also called net income) for the twelve months ending Dec 27, 2025 was $175.44 million, a 34.88% increase year over year.
What was HAE's earnings growth in the past year?
As of Haemonetics's earnings date in Invalid Date, Haemonetics's earnings has grown 42.58% year over year. This is 32.41 percentage points higher than the US Medical Instruments & Supplies industry earnings growth rate of 10.17%. HAE earnings in the past year totalled $175.44 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.